Literature DB >> 11746271

Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate.

A Handisurya1, G E Steiner, U Stix, R C Ecker, S Pfaffeneder-Mantai, D Langer, G Kramer, N Memaran-Dadgar, M Marberger.   

Abstract

BACKGROUND: Pro-inflammatory interleukin (IL)-15 plays a major role in host defense and chronic inflammation by stimulating T-lymphocyte recruitment and growth. Expression of IL-15 and IL-15 receptor (IL-15R) in human prostate was examined.
METHODS: Normal and benign hyperplastic (BPH) prostate specimens (n = 23) were analyzed for IL-15 and IL-15Ralpha-chain expression by immunohistochemistry and Real-Time-PCR/RT-PCR. Regulation of prostatic stromal cell (PSC) IL-15 mRNA and effect of IL-15 on prostatic cell growth were analysed in vitro.
RESULTS: In normal prostate, anti-IL-15 and anti-IL-15Ralpha-chain reactivity were restricted to smooth muscle and stromal cells. However, in BPH, in addition epithelial cells frequently exhibited discrete anti-IL-15R and often intense, membranous anti-IL-15 reactivity. IL-15/IL-15R mRNA were detected in all prostatic cells types. In BPH tissues, IL-15 mRNA content was variable (15-fold). IL-15 mRNA synthesis of PSC was significantly up-regulated by IFN-gamma. Furthermore IL-15 strongly stimulated the growth of BPH-T-lymphocytes and weakly that of carcinoma cell lines, but not of stromal cells.
CONCLUSIONS: Overexpression of IL-15 and IL-15Ralpha-chain in BPH and massive proliferation of BPH-T-lymphocytes induced by IL-15 suggest a role for IL-15 in prostatic inflammation. Since IFN-gamma, a T-lymphocyte product, stimulates prostatic IL-15 production; chronic inflammation might be triggered by this paracrine loop. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11746271     DOI: 10.1002/pros.10020

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  23 in total

1.  The picture of the prostatic lymphokine network is becoming increasingly complex.

Authors:  Georg E Steiner; Bob Djavan; Gero Kramer; Alessandra Handisurya; Martin Newman; Chung Lee; Michael Marberger
Journal:  Rev Urol       Date:  2002

2.  [Chronic inflammation as promotor and treatment target in benign prostate hyperplasia (BPH) and in prostate cancer].

Authors:  G Kramer; D Mitteregger; A Maj-Hes; S Sevchenco; W Brozek
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 3.  Role of interleukins, IGF and stem cells in BPH.

Authors:  Ian D McLaren; Travis J Jerde; Wade Bushman
Journal:  Differentiation       Date:  2011-08-23       Impact factor: 3.880

Review 4.  The functional role of reactive stroma in benign prostatic hyperplasia.

Authors:  Isaiah G Schauer; David R Rowley
Journal:  Differentiation       Date:  2011-06-12       Impact factor: 3.880

Review 5.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

6.  Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Authors:  Jeannette M Schenk; Alan R Kristal; Marian L Neuhouser; Catherine M Tangen; Emily White; Daniel W Lin; Mario Kratz; Ian M Thompson
Journal:  Am J Epidemiol       Date:  2010-02-08       Impact factor: 4.897

7.  Il-1 beta-induced post-transition effect of NF-kappaB provides time-dependent wave of signals for initial phase of intrapostatic inflammation.

Authors:  Eugene V Vykhovanets; Sanjeev Shukla; Gregory T MacLennan; Olena V Vykhovanets; Donald R Bodner; Sanjay Gupta
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

8.  The senescence-associated secretory phenotype promotes benign prostatic hyperplasia.

Authors:  Paz Vital; Patricia Castro; Susan Tsang; Michael Ittmann
Journal:  Am J Pathol       Date:  2014-01-13       Impact factor: 4.307

9.  Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.

Authors:  Kouji Izumi; Lei Li; Chawnshang Chang
Journal:  Clin Investig (Lond)       Date:  2014-10-01

10.  Etiopathogenesis of benign prostatic hypeprlasia.

Authors:  Jie Tang; Jingchun Yang
Journal:  Indian J Urol       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.